PAPD5 inhibitors and PAPD7 inhibitors for the treatment of hepatitis B infection

Inhibiting PAPD5 and/or PAPD7 expression or activity in HBV infection suppresses HBsAg and HBeAg secretion, addressing the limitations of current therapies and reducing chronic HBV infection and transmission.

JP2026091838APending Publication Date: 2026-06-04F HOFFMANN LA ROCHE & CO AG
0 Cites 0 Cited by

Patent Information

Application Number
JP2026015630
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2016-06-17
Filing Date
2026-02-02
Publication Date
2026-06-04

AI Technical Summary

Technical Problem

Current therapies for hepatitis B virus (HBV) infection, such as nucleoside/nucleotide analogs, only weakly suppress HBsAg clearance and fail to effectively reduce HBeAg levels, leading to chronic infections and high transmission rates, particularly in maternal-to-fetal transmission.

Method used

Identify and utilize compounds that inhibit PAPD5 and/or PAPD7 expression or activity, or bind to these proteins to reduce HBsAg and HBeAg secretion, thereby suppressing HBV infection through a screening method involving PAPD5 and/or PAPD7 polypeptides and cells expressing these proteins.

Benefits of technology

The identified compounds significantly inhibit HBsAg and HBeAg secretion, effectively reducing chronic HBV infection and transmission, with a potential to prevent HBV infection in newborns from HBeAg-positive mothers.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a method for identifying compounds that prevent, improve, and / or suppress hepatitis B virus (HBV) infection. [Solution] The present invention relates to a method for identifying compounds that (i) reduce the expression and / or activity of PAP-related domain-containing protein 5 (PAPD5) and / or PAP-related domain-containing protein 7 (PAPD7) and / or (ii) bind to PAPD5 and / or PAPD7 and inhibit the proliferation of HBV, as compounds for preventing, improving and / or suppressing HBV infection. The present invention also provides PAPD5 and / or PAPD7 inhibitors for use in the treatment and / or prevention of HBV infection, as well as mixed formulations comprising PAPD5 inhibitors and PAPD7 inhibitors for simultaneous or sequential use in the treatment and / or prevention of HBV infection. Pharmaceutical compositions for use in the treatment and / or prevention of HBV infection, and methods for monitoring treatment outcomes during the treatment of HBV infection are also included in the present invention.
Need to check novelty before this filing date? Find Prior Art